We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

CIT Announces Availability of Dried Blood Spot Technique for Bioanalytical Services


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CIT Announces Availability of Dried Blood Spot Technique for Bioanalytical Services"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
CIT, an independent preclinical contract research organization (CRO), announces that it is now offering the Dried Blood Spot (DBS) technique to its clients worldwide. The new service is in line with CIT’s policy of continuous enhancements to the range it offers its customers.

The DBS technique is a sample processing and storage method in which small samples of blood are taken, dried on pre-treated paper cards and stored for subsequent analysis. This technique avoids the preparation of plasma, and permits the use of very small samples for pharmacokinetic and/or toxicokinetic analyses. It also facilitates sample storage, archiving and shipment. At the time of analysis, the drug is recovered from the paper card by solvent extraction and analyzed by traditional chromatographic (or other) techniques.

Many small molecule therapeutics can benefit from the DBS approach. Preliminary verification in the laboratory will determine its applicability. Pediatric medicine was among the first to use the technique and it is now arousing great interest in other fields.

Adoption of the DBS technique will bring ethical, scientific and cost benefits to CIT clients. For example, the small sample volume means that in many cases rodent studies will not need to use extra groups of animals just for pharmacokinetic monitoring, thus bringing a corresponding reduction in animal use. In the best cases, it will be possible to obtain a complete pharmacokinetic profile from a single rodent animal.

The technique can be used across the range of discovery and regulatory toxicology, pharmacology and pharmacokinetics studies. It will also facilitate the performance of studies with animals having a limited blood volume.

This guideline-compliant study confirmed that acceptable values are obtained for validation parameters when the DBS technique is used. Over the next few months CIT will be presenting work on the DBS technique at several meetings such as American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and the European Bioanalysis Forum (EBF).
Advertisement